The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone
Open accessAbstract
Background and purpose: There is high interindividual variability in the activity of drug‐metabolizing enzymes catalysing the oxidation of oxycodone [cytochrome P450 (CYP) 2D6 and 3A], due to genetic polymorphisms and/or drug–drug interactions. The effects of CYP2D6 and/or CYP3A activity modulation on the pharmacokinetics of oxycodone remains poorly explored. Experimental approach: A randomized crossover double‐blind placebo‐controlled study was performed with 10 healthy volunteers genotyped for CYP2D6 [six extensive (EM), two deficient (PM/IM) and two ultrarapid metabolizers (UM)]. The volunteers randomly received on five different occasions: oxycodone 0.2 mg·kg−1 and placebo; oxycodone and quinidine (CYP2D6 inhibitor); oxycodone and ketoconazole (CYP3A inhibitor); oxycodone and quinidine+ketoconazole; placebo. Blood samples for plasma concentrations of oxycodone and metabolites (oxymorphone, noroxycodone and noroxymorphone) were collected for 24 h after dosing. Phenotyping for CYP2D6 (with dextromethorphan) and CYP3A (with midazolam) were assessed at each session. Key results: CYP2D6 activity was correlated with oxymorphone and noroxymorphone AUCs and C max(−0.71 < Spearman correlation coefficient ρs < −0.92). Oxymorphone C max was 62% and 75% lower in PM than EM and UM. Noroxymorphone C max reduction was even more pronounced (90%). In UM, oxymorphone and noroxymorphone concentrations increased whereas noroxycodone exposure was halved. Blocking CYP2D6 (with quinidine) reduced oxymorphone and noroxymorphone C max by 40% and 80%, and increased noroxycodone AUC∞by 70%. Blocking CYP3A4 (with ketoconazole) tripled oxymorphone AUC∞and reduced noroxycodone and noroxymorphone AUCs by 80%. Shunting to CYP2D6 pathway was observed after CYP3A4 inhibition. Conclusions and implications: Drug–drug interactions via CYP2D6 and CYP3A affected oxycodone pharmacokinetics and its magnitude depended on CYP2D6 genotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Cited by
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shen, D. D., Callaghan, J. T., Sadhasivam, S., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.254 · Cited by 680
Paice, J. A., Portenoy, R., Lacchetti, C., Campbell, T., Cheville, A., Citron, M., Constine, L. S., Cooper, A., Glare, P., Keefe, F., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5206 · Cited by 599
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., Kharasch, E. D., & Skaar, T. C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.287 · Cited by 371
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Self-citation
Metadata
- Authors
- Samer, C., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C., Rebsamen, M., Rossier, M., Hochstrasser, D., Dayer, P., & Desmeules, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-05-24
- Volume
- 160
- Issue
- 4
- Pages
- 907-918
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1955305547
- Cited by
- 166
- References
- 1
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.00673.x
- The paper
- Samer, C., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C., Rebsamen, M., Rossier, M., Hochstrasser, D., Dayer, P., & Desmeules, J. (2010). The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.00673.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.